Generic biotech crops jeopardized by over-regulation

The Competitive Enterprise Institute released a new study finding that regulatory policy could inhibit the development of a generic market for biotech seeds once patents on those varieties expires.

Over the next decade, the patents on nearly two dozen of the most popular biotech crop traits will expire, and farmers in the U.S. and abroad are eager to get access to low-cost, generic versions of those seeds. But most biotech crop traits must be reapproved every three to five years, and the process requires applicants to have access to confidential business information held by the original product developers. This establishes a potentially impassable roadblock to the future of affordable, generic biotech products.

View the original article here: Generic biotech crops jeopardized by over-regulation – Western Farm Press

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
seralinistud

Gilles-Éric Séralini: Activist professor and face of anti-GMO industry

The French biologist and his research team--funded by the Rodale ...
vandana shiva

Vandana Shiva: ‘Rock Star’ of GMO protest movement has anti-science history

In a 2012 interview, Bill Moyers referred to Vandana Shiva as ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend